Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of EPZ-5676 continuous intravenous infusion in relapsed or refractory leukemia and advanced hematologic malignancies
NL-OMON41336Phase 1Active, not recruiting
- Sponsor
- Epizyme, Inc.
- Start
- Jun 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pinometostat in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 5 more (2 arms), sponsored by Epizyme, Inc. Primary endpoints: Dose-limiting toxicities and MTD/RP2D determination and Safety and tolerability. Started Jun 2014; status: active, not recruiting.
02
Drugs
pinometostat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NL-OMON41336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41336.